Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ross Products

This article was originally published in The Tan Sheet

Executive Summary

Health Source soy protein powder will be introduced to retail outlets including Wal-Mart, CVS, Walgreens, Rite Aid, Eckerd, Genovese, Albertson's and Drug Emporium July 1. The Abbott Labs division product, which "may help promote healthy cholesterol levels," was previously available as Take Care via direct mail. As part of an exclusive agreement with Protein Technologies, Inc., Health Source contains PTI's Supro XG isolated soy protein. Promotional materials state one serving of the powder also provides 70% of the Recommended Daily Intake for calcium and 25% for vitamin D. Print ads for the product, developed by New York City-based Gotham, will drop in magazines including Prevention, People, Health and McCalls later this summer; Ross also is detailing the powder to physicians. The product in 8.9 oz. cans will retail for $9.99 and come in vanilla, chocolate, strawberry and unflavored versions

Related Content

Topics

UsernamePublicRestriction

Register

PS089970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel